Immunological mechanisms of vaccine-induced protection against COVID-19 in humans

Cited by (513)

Items 101–200 of 513

1. Memory B cell diversity: insights for optimized vaccine design
   Joshua J.C. McGrath, Lei Li, Patrick C. Wilson · 2022 · Trends in Immunology
2. Effectiveness and Safety of COVID-19 Vaccinations: An Umbrella Meta-Analysis
   Zhu Liduzi Jiesisibieke, Wenyi Liu, Yupei Yang, Ching-Wen Chien, Tao‐Hsin Tung · 2023 · International Journal of Public Health
3. Crowding and vaccination: Tourist's two-sided perception on crowding and the moderating effect of vaccination status during COVID-19 pandemic
   Zhenghu Nie, Li Xu, Honglei Zhang, Yihan Cao, Chi Zhang, Jingxian Pan, Jie Zhang · 2022 · Journal of Destination Marketing & Management
4. Glucocorticoids’ treatment impairs the medium-term immunogenic response to SARS-CoV-2 mRNA vaccines in Systemic Lupus Erythematosus patients
   Silvia Garcia-Cirera, Joan Calvet, Antonio Berenguer, Edwards Pradenas, Sílvia Marfil, Marta Massanella, Lourdes Mateu, Benjamin Trinité, María Llop-Vilaltella, Marta Arévalo et al. · 2022 · Scientific Reports
5. Hybrid immunity against COVID-19 in different countries with a special emphasis on the Indian scenario during the Omicron period
   Manojit Bhattacharya, Ashish Ranjan Sharma, Kuldeep Dhama, Govindasamy Agoramoorthy, Chiranjib Chakraborty · 2022 · International Immunopharmacology
6. Impact of SARS-CoV-2 vaccination on systemic immune responses in people living with HIV
   Clara Bessen, Carlos Plaza‐Sirvent, Agit Simsek, Jaydeep Bhat, Corinna Sophie Marheinecke, Doris Urlaub, Petra Bonowitz, Sandra Buße, Sabrina Schumann, Elena Vidal Blanco et al. · 2022 · Frontiers in Immunology
7. Characterizing the cellular and molecular variabilities of peripheral immune cells in healthy recipients of BBIBP-CorV inactivated SARS-CoV-2 vaccine by single-cell RNA sequencing
   Tong, Renyang, Luo, Lingjie, Zhao, Yichao, Sun, Mingze, Li, Ronghong, Zhong, Jianmei, Chen, Yifan, Hu, Liuhua, Li, Zheng, Shi, Jianfeng et al. · 2023 · Emerging Microbes & Infections
8. Immunogenicity of the third and fourth BNT162b2 mRNA COVID-19 boosters and factors associated with immune response in patients with SLE and rheumatoid arthritis
   Theerada Assawasaksakul, Seelwan Sathitratanacheewin, Preeyaporn Vichaiwattana, Nasamon Wanlapakorn, Yong Poovorawan, Yingyos Avihingsanon, Nawaporn Assawasaksakul, Wonngarm Kittanamongkolchai · 2022 · Lupus Science & Medicine
9. Severe Breakthrough COVID-19 Cases during Six Months of Delta Variant (B.1.617.2) Domination in Poland
   Piotr Rzymski, Monika Pazgan−Simon, Juliusz Kamerys, Anna M. Moniuszko-Malinowska, Katarzyna Sikorska, Joanna Wernik, Dorota Zarębska‐Michaluk, Łukasz Supronowicz, Barbara Sobala‐Szczygieł, Agata Skrzat‐Klapaczyńska et al. · 2022 · Vaccines
10. Adenoviral-vectored next-generation respiratory mucosal vaccines against COVID-19
    Sam Afkhami, Alisha Kang, Vidthiya Jeyanathan, Zhou Xing, Mangalakumari Jeyanathan · 2023 · Current Opinion in Virology
11. High‐resolution analysis of individual spike peptide‐specific CD4 + T‐cell responses in vaccine recipients and COVID‐19 patients
    Hendrik Karsten, Leon Cords, Tim Westphal, M. Knapp, T. Brehm, L. Hermanussen, T. Omansen, S. Schmiedel, R. Woost, V. Ditt et al. · 2022 · Clinical & Translational Immunology
12. Cancer vaccines: from an immunology perspective
    Shania Makker, Charlotte Galley, Clare L. Bennett · 2023 · Immunotherapy Advances
13. COVID-19 related acute necrotizing encephalopathy with extremely high interleukin-6 and RANBP2 mutation in a patient with recently immunized inactivated virus vaccine and no pulmonary involvement
    2022
14. Understanding the Role of Type I Interferons in Cutaneous Lupus and Dermatomyositis: Toward Better Therapeutics
    2024
15. A mucosal antibody response is induced by intra-muscular SARS-CoV-2 mRNA vaccination
    2021
16. Quantitative multiorgan proteomics of fatal COVID‐19 uncovers tissue‐specific effects beyond inflammation
    Lisa Schweizer, Tina Schaller, Maximilian Zwiebel, Özge Karayel, Johannes Müller, Wen‐Feng Zeng, Sebastian Dintner, Thierry M. Nordmann, Klaus Hirschbühl, Bruno Märkl et al. · 2023 · EMBO Molecular Medicine
17. Inexpensive High-Throughput Multiplexed Biomarker Detection Using Enzymatic Metallization with Cellphone-Based Computer Vision
    Neda Rafat, Lee Brewer, Nabojeet Das, Dhruti J. Trivedi, Balazs K. Kaszala, Aniruddh Sarkar · 2023 · ACS Sensors
18. Mucosal immunization with Lactiplantibacillus plantarum-displaying recombinant SARS-CoV-2 epitopes on the surface induces humoral and mucosal immune responses in mice
    In‐Chan Hwang, Valerie Diane Valeriano, Ji Hoon Song · 2023 · Microbial Cell Factories
19. Capillary leak syndrome following COVID-19 vaccination: Data from the European pharmacovigilance database Eudravigilance
    2022
20. Vaccine-induced immune thrombotic thrombocytopenia: what do we know hitherto?
    Renat Roytenberg, Adolfo García‐Sastre, Wei Li · 2023 · Frontiers in Medicine
21. Recent Advances of Trained immunity in Macrophages
    2025
22. Phase I interim results of a phase I/II study of the IgG-Fc fusion COVID-19 subunit vaccine, AKS-452
    Yester F. Janssen, Eline A. Feitsma, Hendrikus Hessel Boersma, David G. Alleva, Thomas M. Lancaster, Thillainaygam Sathiyaseelan, Sylaja Murikipudi, Andrea R. Delpero, Melanie M. Scully, Ramya Ragupathy et al. · 2022 · Vaccine
23. Immediate Hypersensitivity Reactions Induced by COVID-19 Vaccines: Current Trends, Potential Mechanisms and Prevention Strategies
    Wen‐Hung Chung, Ivan Arni C. Preclaro, Wen‐Hung Chung, Chuang‐Wei Wang · 2022 · Biomedicines
24. Schistosoma mansoni infection alters the host pre-vaccination environment resulting in blunted Hepatitis B vaccination immune responses
    Roshell Muir, Talibah U. Metcalf, Slim Fourati, Yannic C. Bartsch, Jacqueline Kyosiimire–Lugemwa, Glenda Canderan, Galit Alter, Enoch Muyanja, Brenda Apio Okech, Teddy Namatovu et al. · 2023 · PLoS neglected tropical diseases
25. Various painful oral adverse reactions following COVID-19 vaccination: a case series
    Youngwoo Chun, Ji-Hee Jang, Jung Hwan Jo, Ji Woon Park · 2022 · BMC Oral Health
26. Anti-TNFα Treatment Impairs Long-Term Immune Responses to COVID-19 mRNA Vaccine in Patients with Inflammatory Bowel Diseases
    Keren Masha Rabinowitz, Michal Navon, Hadar Edelman-Klapper, Eran Zittan, Ariella Bar‐Gil Shitrit, Idan Goren, Irit Avni‐Biron, Jacob E. Ollech, Lev Lichtenstein, Hagar Banai-Eran et al. · 2022 · Vaccines
27. Innate and Adaptive Immune Responses in the Upper Respiratory Tract and the Infectivity of SARS-CoV-2
    Ranjan Ramasamy · 2022 · Viruses
28. Immune response and homeostasis mechanism following administration of BBIBP-CorV SARS-CoV-2 inactivated vaccine
    Jianhua Yin, Yingze Zhao, Fubaoqian Huang, Yunkai Yang, Yaling Huang, Zhenkun Zhuang, Yanxia Wang, Zhifeng Wang, Xiumei Lin, Yuhui Zheng et al. · 2022 · The Innovation
29. Recombinant Adjuvanted Zoster Vaccine and Reduced Risk of Coronavirus Disease 2019 Diagnosis and Hospitalization in Older Adults
    Katia J. Bruxvoort, Bradley K. Ackerson, Lina S. Sy, Amit B. Bhavsar, Hung Fu Tseng, Ana Florea, Yi Luo, Yun Tian, Zendi Solano, Robyn Widenmaier et al. · 2021 · The Journal of Infectious Diseases
30. Intranasal or airborne transmission-mediated delivery of an attenuated SARS-CoV-2 protects Syrian hamsters against new variants
    Charles B. Stauft, Prabhuanand Selvaraj, Felice D’Agnillo, Clement A. Meseda, Shufeng Liu, Cyntia L. Pedro, Kotou Sangare, Christopher Z. Lien, Jerry P. Weir, Matthew F. Starost et al. · 2023 · Nature Communications
31. Immunomodulation of COVID‐19 severity by helminth co‐infection: Implications for COVID‐19 vaccine efficacy
    Yibeltal Akelew, Andualem Henok, Endris Ebrahim, Aytenew Atnaf, Wasihun Hailemichael · 2021 · Immunity Inflammation and Disease
32. The allocation of COVID-19 vaccines and antivirals against emerging SARS-CoV-2 variants of concern in East Asia and Pacific region: A modelling study
    Kathy S. M. Leung, Mark Jit, Gabriel Matthew Leung, Joseph Tsz Kei Wu · 2022 · The Lancet Regional Health - Western Pacific
33. A randomized phase I/II safety and immunogenicity study of the Montanide-adjuvanted SARS-CoV-2 spike protein-RBD-Fc vaccine, AKS-452
    Eline A. Feitsma, Yester F. Janssen, Hendrikus Hessel Boersma, Yannick van Sleen, Debbie van Baarle, David G. Alleva, Thomas M. Lancaster, Thillainaygam Sathiyaseelan, Sylaja Murikipudi, Andrea R. Delpero et al. · 2023 · Vaccine
34. Inactivated COVID-19 vaccines: durability of Covaxin/BBV152 induced immunity against variants of concern
    Nathella Pavan Kumar, V.V. Banurekha, C. P. Girish Kumar, Arul Nancy, Chandrasekaran Padmapriyadarshini, Sakila Shankar, Luke Elizabeth Hanna, Manoj Vasanth Murhekar, Kanchan Devi, Subash Babu · 2022 · Journal of Travel Medicine
35. Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines
    Guy Cohen, Pawornrath Jungsomsri, Jirath Sangwongwanich, Kriangkrai Tawinprai, Taweegrit Siripongboonsitti, Thachanun Porntharukchareon, Kasiruck Wittayasak, Nawarat Thonwirak, Kamonwan Soonklang, Gaidganok Sornsamdang et al. · 2022 · Human Vaccines & Immunotherapeutics
36. Humoral and Cellular Immune Responses to Vector, Mix-and-Match, or mRNA Vaccines against SARS-CoV-2 and the Relationship between the Two Immune Responses
    Minjeong Nam, Seung Gyu Yun, Sang‐Wook Kim, Chris Gunwoo Kim, Jae Hyun Cha, Cheonghwa Lee, Seunghyuk Kang, Seul Gi Park, Sun Bean Kim, Ki-Byung Lee et al. · 2022 · Microbiology Spectrum
37. Modeling the Enzymatic Mechanism of the SARS-CoV-2 RNA-Dependent RNA Polymerase by DFT/MM-MD: An Unusual Active Site Leading to High Replication Rates
    2022
38. Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome
    Flávio Signorelli, Gustavo Guimarães Moreira Balbi, Nádia Emi Aikawa, Clóvis A. Silva, Léonard de Vinci Kanda Kupa, Ana Cristina de Medeiros Ribeiro, Emily Figueiredo Neves Yuki, Sandra Gofinet Pasoto, Carla Gonçalves Schahin Saad, Eduardo Ferreira Borba et al. · 2022 · Lupus
39. Autophagy and evasion of the immune system by SARS-CoV-2. Structural features of the non-structural protein 6 from wild type and Omicron viral strains interacting with a model lipid bilayer
    Bignon, Emmanuelle, Marazzi, Marco, Grandemange, Stéphanie, Monari, Antonio · 2022 · Chemical Science
40. Intranasal delivery of a subunit protein vaccine provides protective immunity against JN.1 and XBB-lineage variants
    Hong Lei, Weiqi Hong, Jingyun Yang, Cai He, Yanan Zhou, Yu Zhang, Aqu Alu, Jie Shi, Jian Liu, Furong qin et al. · 2024 · Signal Transduction and Targeted Therapy
41. Immunological Mechanisms of Vaccine-Induced Protection against SARS-CoV-2 in Humans
    Keshav Goyal, Harsh Goel, Pritika Baranwal, Anisha Tewary, Aman Dixit, Avanish Kumar Pandey, Mercilena Benjamin, Pranay Tanwar, Abhijit Dey, Fahad Khan et al. · 2021 · Immuno
42. CD4+ T Cell Immune Specificity Changes After Vaccination in Healthy And COVID-19 Convalescent Subjects
    Laura Esparcia-Pinedo, Pedro Martínez‐Fleta, Noelia Ropero, Paula Vera-Tomé, Hugh T. Reyburn, José M. Casasnovas, José Miguel Rodrı́guez-Frade, Mar Valés‐Gómez, Carlos Vilches, Enrique Martín‐Gayo et al. · 2022 · Frontiers in Immunology
43. Antibodies targeting conserved non-canonical antigens and endemic coronaviruses associate with favorable outcomes in severe COVID-19
    Sai Preetham Peddireddy, Syed Ashiqur Rahman, Anthony Richard Cillo, Godhev K. Manakkat Vijay, Ashwin Somasundaram, Creg J. Workman, William Bain, Bryan J. McVerry, Barbara A. Methé, Janet S. Lee et al. · 2022 · Cell Reports
44. DS-5670a, a novel mRNA-encapsulated lipid nanoparticle vaccine against severe acute respiratory syndrome coronavirus 2: Results from a phase 2 clinical study.
    K. Toyama, T. Eto, Kenji Takazawa, Shinji Shimizu, T. Nakayama, K. Furihata, Y. Sogawa, M. Kumazaki, Nao Jonai, Satoko Matsunaga et al. · 2023 · Vaccine
45. Efficacy and safety of mRNA and AstraZeneca COVID-19 vaccines in patients with autoimmune rheumatic diseases: A systematic review
    Anwar Ibrahim Joudeh, Abdu Qaid Lutf, Salah Mahdi, Gui Tong Tran · 2023 · Vaccine
46. Recent Developments in the Understanding of Immunity, Pathogenesis and Management of COVID-19
    Aram Yegiazaryan, Arbi Abnousian, Logan J. Alexander, Ali Badaoui, Brandon Flaig, Nisar Sheren, Armin Aghazarian, Dijla Alsaigh, Arman Amin, Akaash Mundra et al. · 2022 · International Journal of Molecular Sciences
47. The effectiveness of Vaxzevria and CoronaVac vaccines: A nationwide longitudinal retrospective study of 61 million Brazilians (VigiVac-COVID19).
    2021
48. Diagnostic performance between in-house and commercial SARS-CoV-2 serological immunoassays including binding-specific antibody and surrogate virus neutralization test (sVNT)
    Poramed Winichakoon, Jiraprapa Wipasa, Kriangkrai Chawansuntati, Parichat Salee, Tavitiya Sudjaritruk, Saowaluck Yasri, Chantana Khamwan, Rungnapa Peerakam, Dararat Dankai, Romanee Chaiwarith · 2023 · Scientific Reports
49. SARS-CoV-2 mRNA-vaccine candidate; COReNAPCIN®, induces robust humoral and cellular immunity in mice and non-human primates
    Reza Alimohammadi, Meysam Porgoo, Mohamad Eftekhary, Seyed Hossein Kiaie, Ehsan Ansari Dezfouli, Maryam Dehghani, Kaveh Nasrollahi, Talieh Malekshahabi, Maryam Heidari, Sedigheh Pouya et al. · 2022 · npj Vaccines
50. Homology‐based classification of accessory proteins in coronavirus genomes uncovers extremely dynamic evolution of gene content
    Diego Forni, Rachele Cagliani, Cristian Molteni, Federica Arrigoni, Alessandra Mozzi, Mario Clerici, Luca DE GIOIA, Manuela Sironi · 2022 · Molecular Ecology
51. Measurements of Anti-SARS-CoV-2 Antibody Levels after Vaccination Using a SH-SAW Biosensor
    2022
52. Targeting Specific Checkpoints in the Management of SARS-CoV-2 Induced Cytokine Storm
    Abdullahi Rabiu Abubakar, Rahnuma Ahmad, Adekunle Babajide Rowaiye, Sayeeda Rahman, Katia Iskandar, Siddhartha Dutta, Angus Nnamdi Oli, Sameer Dhingra, Maryam Abba Tor, Ayukafangha Etando et al. · 2022 · Life
53. Heterologous SARS‐CoV ‐2 IgA neutralising antibody responses in convalescent plasma
    Samantha K. Davis, Kevin John Selva, Ester López, Ebene R. Haycroft, Wen Shi Lee, Adam K. Wheatley, Jennifer A. Juno, Amy Adair, Phillip Pymm, Samuel J. Redmond et al. · 2022 · Clinical & Translational Immunology
54. Surviving the Storm: Cytokine Biosignature in SARS-CoV-2 Severity Prediction
    Rahnuma Ahmad, Mainul Haque · 2022 · Vaccines
55. Immunogenicity and safety of an intradermal fractional third dose of ChAdOx1 nCoV-19/AZD1222 vaccine compared with those of a standard intramuscular third dose in volunteers who previously received two doses of CoronaVac: A randomized controlled trial
    Kriangkrai Tawinprai, Taweegrit Siripongboonsitti, Thachanun Porntharukchareon, Kasiruck Wittayasak, Nawarat Thonwirak, Kamonwan Soonklang, Gaidganok Sornsamdang, Chirayu Udomsakdi Auewarakul, Nithi Mahanonda · 2022 · Vaccine
56. Structural Profiles of SARS-CoV-2 Variants in India
    Soumyananda Chakraborti, Jasmita Gill, Ritu Goswami, Sanjeev Kumar, Anmol Chandele, Amit Raj Sharma · 2022 · Current Microbiology
57. A Case Series on the COVID-19 Vaccines and Possible Immune-Related Adverse Events: A New Challenge for the Rheumatologists
    2022
58. Targeting Inflammasome Activation in COVID-19: Delivery of RNA Interference-Based Therapeutic Molecules
    Lealem Gedefaw, Sami Ullah, Thomas M. H. Lee, Shea Ping Yip, Chien‐Ling Huang · 2021 · Biomedicines
59. Markers of Memory CD8 T Cells Depicting the Effect of the BNT162b2 mRNA COVID-19 Vaccine in Japan
    Hiroyuki Kondo, Takahiro Kageyama, Shigeru Tanaka, Shin‐ichi Tsukumo, Kunihiro Otsuka, Yoichi Mashimo, Yoshihiro Onouchi, Hiroshi Nakajima, Koji Yasutomo · 2022 · Frontiers in Immunology
60. The dynamics of quantitative SARS‐CoV‐2 antispike IgG response to BNT162b2 vaccination
    Shun Kaneko, Masayuki Kurosaki, Toru Sugiyama, Yuka Takahashi, Yoshimi Yamaguchi, Masayuki Nagasawa, Namiki Izumi · 2021 · Journal of Medical Virology
61. Humoral immune response characterization of heterologous prime-boost vaccination with CoronaVac and BNT162b2
    Florencia Rammauro, Federico Carrión, Natalia Olivero‐Deibe, Martín Fló, Ana Ferreira, Otto Pritsch, Sergio Bianchi · 2022 · Vaccine
62. A longitudinal analysis of humoral, T cellular response and influencing factors in a cohort of healthcare workers: Implications for personalized SARS-CoV-2 vaccination strategies
    Eleonora Sabetta, Maddalena Noviello, Clara Sciorati, Marco Viganò, Rebecca DE LORENZO, Valeria Beretta, Veronica Valtolina, Chiara Di Resta, Giuseppe Banfi, Davide Ferrari et al. · 2023 · Frontiers in Immunology
63. Humoral Immune Response of BNT162b2 and CoronaVac Vaccinations in Hemodialysis Patients: A Multicenter Prospective Cohort
    René Clavero, Alfredo Parra-Lucares, Gabriel Méndez-Valdés, Eduardo Villa, Karin Bravo, Evelyn Mondaca, Josseline Aranda, Rose Brignardello, Cynthia Gajardo, Angelica Ordenes et al. · 2022 · Vaccines
64. Development of nanoparticles incorporated with quercetin and ACE2-membrane as a novel therapy for COVID-19
    Jia‐You Fang, Kuo‐Yen Huang, Tong‐Hong Wang, Zih‐Chan Lin, Chih‐Cheng Chen, Sui-Yuan Chang, En-Li Chen, Tai-Ling Chao, Shuenn‐Chen Yang, Pan-Chyr Yang et al. · 2024 · Journal of Nanobiotechnology
65. Immune Responses Following the First Dose of the Sputnik V (Gam-COVID-Vac)
    Chandima Jeewandara, Suranga Fernando, Pradeep Darshana Pushpakumara, Shyrar Tanussiya Ramu, Achala Kamaladasa, Banuri Gunasekara, Inoka Sepali Aberathna, Heshan Kuruppu, Thushali Ranasinghe, Shashika Dayarathne et al. · 2021 · Scientific Reports
66. Longitudinal proteomic investigation of COVID-19 vaccination
    2023
67. T Cell Activating Thermostable Self‐Assembly Nanoscaffold Tailored for Cellular Immunity Antigen Delivery
    2023
68. COVID‐19, obesity, and immune response 2 years after the pandemic: A timeline of scientific advances
    Mayara Belchior‐Bezerra, Rafael Silva Lima, Nayara Ingrid Medeiros, Juliana de Assis Silva Gomes · 2022 · Obesity Reviews
69. Safety, immunogenicity, and efficacy of an mRNA COVID-19 vaccine (RQ3013) given as the fourth booster following three doses of inactivated vaccines: a double-blinded, randomised, controlled, phase 3b trial
    Xiaoqiang Liu, Zhonghan Sun, Zhongfang Wang, Jingjing Chen, Qianhui Wu, Yan Zheng, Xiaoyun Yang, Luhui Mo, Xuemei Yan, Wei Li et al. · 2023 · EClinicalMedicine
70. Evaluation of PastoCovac plus vaccine as a booster dose on vaccinated individuals with inactivated COVID-19 vaccine
    Behrokh Farahmand, Mona Sadat Larijani, Fatemeh Fotouhi, Alireza Biglari, Rahim Sorouri, Fahimeh Bagheri Amiri, Ali Eslamifar, Tahmineh Jalali, ‪Mostafa Salehi-Vaziri, Mohammad Banifazl et al. · 2023 · Heliyon
71. Monitoring of Both Humoral and Cellular Immunities Could Early Predict COVID-19 Vaccine Efficacy Against the Different SARS-CoV2 Variants
    Manon Vogrig, Anne-Emmanuelle Berger, Thomas Bourlet, Louis Waeckel, Alice Haccourt, Alice Haccourt Chanavat, David Hupin, Frédéric Roche, Élisabeth Botelho-Nevers, Bruno Pozzetto et al. · 2022 · Journal of Clinical Immunology
72. Potential of mRNA-based vaccines for the control of tick-borne pathogens in one health perspective
    Elizabeth González Cueto, José de la Fuente, César López‐Camacho · 2024 · Frontiers in Immunology
73. Co-Delivery of Novel Synthetic TLR4 and TLR7/8 Ligands Adsorbed to Aluminum Salts Promotes Th1-Mediated Immunity against Poorly Immunogenic SARS-CoV-2 RBD
    Karthik Siram, Stephanie K. Lathrop, Walid Abdelwahab, Rebekah D. Tee, Clara J. Davison, Haley A. Partlow, Jay T. Evans, David J. Burkhart · 2023 · Vaccines
74. How Do Anti-SARS-CoV-2 mRNA Vaccines Protect from Severe Disease?
    Maurizio Federico · 2022 · International Journal of Molecular Sciences
75. The immunopathogenesis of SARS-CoV-2 infection: Overview of lessons learned in the first 5 years
    Otto O. Yang · 2025 · The Journal of Immunology
76. SARS-CoV-2 Spike Protein Vaccine-Induced Immune Imprinting Reduces Nucleocapsid Protein Antibody Response in SARS-CoV-2 Infection
    2022
77. Multi-omics in COVID-19: Seeing the unseen but overlooked in the clinic
    2022
78. Immune response of heterologous versus homologous prime-boost regimens with adenoviral vectored and mRNA COVID-19 vaccines in immunocompromised patients
    Chang Chu, Anne Schönbrunn, Dorothea Fischer, Yvonne Liu, Johann-Georg Hocher, Jutta Weinerth, Kristin Klemm, Volker von Baehr, Bernhard Karl Krämer, Saban Elitok et al. · 2023 · Frontiers in Immunology
79. Immunity in SARS-CoV-2 Infection: Clarity or Mystery? A Broader Perspective in the Third Year of a Worldwide Pandemic
    Katarzyna Kapten, Krzysztof Orczyk, Elżbieta Barbara Smolewska · 2023 · Archivum Immunologiae et Therapiae Experimentalis
80. Seroconversion rate after COVID-19 vaccination in patients with solid cancer: A systematic review and meta-analysis
    Juntao Yin, Yangyang Chen, Yang Li, Xingwang Zhang, Chaoyang Wang · 2022 · Human Vaccines & Immunotherapeutics
81. An assessment of the strategy and status of COVID-19 vaccination in India
    Sneh Lata Gupta, Surbhi Goswami, Ananya Anand, Namrata Naman, P. Kumari, Priyanka Sharma, R. Jaiswal · 2023 · Immunologic research
82. SARS-CoV-2 spike host cell surface exposure promoted by a COPI sorting inhibitor
    Yiqun Li, Mingrui Yang, Yanan Nan, Jiaming Wang, Sanjiao Wang, Dongxiao Cui, Jiajian Guo, Pengfei He, Wenxin Dai, Shuqi Zhou et al. · 2023 · Acta Pharmaceutica Sinica B
83. Neuroimmunology
    2001
84. The changing health impact of vaccines in the COVID-19 pandemic: A modeling study
    Jamie A. Cohen, Robyn M. Stuart, Jasmina Panovska‐Griffiths, Edinah Mudimu, Romesh Abeysuriya, Cliff C. Kerr, Michael Famulare, Daniel J. Klein · 2023 · Cell Reports
85. Integrated antibody and cellular immunity monitoring are required for assessment of the long term protection that will be essential for effective next generation vaccine development
    Eustache Paramithiotis, Christophe Varaklis, Stéphane Pillet, Shahin Shafiani, Mary Pat Lancelotta, Steven R. Steinhubl, Scott Sugden, Matt Clutter, Damien Montamat‐Sicotte, Todd Chermak et al. · 2023 · Frontiers in Immunology
86. The PHH-1V HIPRA vaccine: a new tool in the vaccination strategy against COVID-19
    C. Borralleras Fumaña, Javier Castrodeza, Pilar Arrazola, Carmen Cámara Hijón, José María Eirós Bouza, María Fernández-Prada, Ángel Gil de Miguel, Gloria Mirada Masip, F.A. Moraga Llop, Daniel Ocaña et al. · 2023 · Revista Española de Quimioterapia
87. Impact of Therapeutics on Unified Immunity During Allergic Asthma and Respiratory Infections
    Armando S. Flores-Torres, Amali Eashani Samarasinghe · 2022 · Frontiers in Allergy
88. Pathological Findings in COVID-19 and Non-COVID-19 Vaccine-Associated Lymphadenopathy: A Systematic Review
    Tzy Harn Chua, Angela Maria Takano · 2022 · Journal of Clinical Medicine
89. Role of Cytochrome P450 2C9 in COVID-19 Treatment: Current Status and Future Directions
    Sharoen Yu Ming Lim, Basel Al Bishtawi, Willone Lim · 2023 · European Journal of Drug Metabolism and Pharmacokinetics
90. Add fuel to the fire: Inflammation and immune response in lung cancer combined with COVID-19
    Yanling Ai, Hengyi Wang, Qiao Zheng, Songtao Li, Jingwen Liu, Ju Wen Huang, Jianyuan Tang, Xiangrui Meng · 2023 · Frontiers in Immunology
91. Anti-SARS-CoV-2 vaccination in people with multiple sclerosis: Lessons learnt a year in
    Maura Pugliatti, Hans‐Peter Hartung, Celia Oreja‐Guevara, Carlo Pozzilli, Laura M. Airas, Mona Marwan Alkhawajah, Nikolaos Grigoriadis, Melinda Magyari, Bart V Wijmeersch, Magd Fouad Zakaria et al. · 2022 · Frontiers in Immunology
92. Fully understanding the efficacy profile of the COVID-19 vaccination and its associated factors in multiple real-world settings
    Yunes Panahi, Behzad Einollahi, Fatemeh Beiraghdar, Mohammad Darvishi, Saeid Fathi, Mohammad Javanbakht, Sepehr Shafiee, Reza Akhavan‐Sigari · 2022 · Frontiers in Immunology
93. The COVID-19 vaccine acceptance in Jordan: a meta-analysis and review of the literature.
    2022
94. What are the challenges faced by COVID-19 vaccines?
    Mohnad Abdalla, Amr Ahmed El‐Arabey, Xinyi Jiang · 2021 · Expert Review of Vaccines
95. COVID-19 Vaccination and Clinical Outcomes at a Secondary Referral Hospital During the Delta Variant-dominant Period in West Sumatra, Indonesia
    Didan Ariadapa Rahadi, Elfira Yusri, Syandrez Prima Putra · 2023 · Journal of Preventive Medicine and Public Health
96. Immune Response and Effects of COVID-19 Vaccination in Patients with Lung Cancer—COVID Lung Vaccine Study
    Ainhoa Hernández, Marc Boigués, Eudald Felip, Marc Cucurull, Lucía Notario, Anna Pous, Pere Torres, Marta Benitez, Marina Rodríguez, Bibiana Quirant‐Sánchez et al. · 2022 · Cancers
97. Immunogenicity of repeat COVID-19 mRNA vaccinations in a patient with myasthenia gravis receiving mycophenolate, prednisone, and eculizumab
    2021
98. Protective effect of vaccination on the risk of cardiovascular disease after SARS-CoV-2 infection
    Jihun Song, Seulggie Choi, Seogsong Jeong, Joo Young Chang, Sun Jae Park, Yun Hwan Oh, Ji Soo Kim, Yoosun Cho, Kyeonghyang Byeon, Jun Yong Choi et al. · 2023 · Clinical Research in Cardiology
99. Longitudinal Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Antibody Responses and Identification of Vaccine Breakthrough Infections Among Healthcare Workers Using Nucleocapsid Immunoglobulin G
    Mark Anderson, Michael Stec, Amy Gosha, Taha Mohammad, Michael Boler, Rebeca Tojo Suarez, Dylan Behun, ALAN L. LANDAY, Gavin Cloherty, James N. Moy · 2022 · The Journal of Infectious Diseases
100. Insights From Early Clinical Trials Assessing Response to mRNA SARS-CoV-2 Vaccination in Immunocompromised Patients
     Frédéric Baron, Lorenzo Canti, Kevin K. Ariën, Delphine Kemlin, Isabelle Desombere, Margaux Gerbaux, Pieter Pannus, Yves P. Beguin, Arnaud Marchant, Stéphanie Humblet‐Baron · 2022 · Frontiers in Immunology